🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526756-31-00
Authorised Phase I

A Study to See How a New Compound, Trontinemab Affects the Body and Whether Immune Signals Triggered by it Affect How Other Medicines are Processed

2026-526756-31-00 · tracked via the Priya Life Science EU tracker
Sponsor
F. Hoffmann-La Roche AG
Sponsor type
Pharmaceutical company
Therapeutic area
Mental Disorders
Decision date
04/09/2026
Enrollment target
46
Sites
Germany

Condition studied

Not Applicable

Eligibility

Age group
18-64 years
Sex
Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526756-31-00 on CTIS ↗ ← All trials in the EU